PPARγ and NAD(P)H oxidase system interaction in glycerol-induced acute renal failure: role of gp91phox subunit of NAD(P)H oxidase

References

• Karam H, Bruneval P, Clozel JP, Loffler BM, Bariety J, Clozel M. Role of endothelin in acute renal failure due to rhabdomyolysis in rats. J Pharmacol Exp Ther. 1995;274(1):481–486
   PubMedGoogle Scholar
• Newaz MA, Oyekan AO. Vascular responses to endothelin-1, angiotensin-II, and U46619 in glycerol-induced renal failure. J Cardiovasc Pharmacol. 2001;38(4):569–577
   PubMedGoogle Scholar
• Metnitz P, Fischer M, Bartens C, Steltzer H, Lang T, Druml W. Impact of acute renal failure on antioxidant status in multiple organ failure. Acta Anesthesiol Scand. 2000;44:236–240
   PubMedGoogle Scholar
• Goligorsky MS, Brodsky SV, Noiri E. NO bioavailability, endothelial dysfunction, and acute renal failure: new insights into pathophysiology. Semin Nephrol. 2004;24:316–323
   PubMed Web of Science ®Google Scholar
• Griendling KK, Sorescu D, Ushio-Fukai M. NAD(P)H oxidase: role in cardiovascular biology and disease. Circ Res. 2000;86:494–501
   PubMed Web of Science ®Google Scholar
• Chabrashvili T, Tojo A, Onozato ML, et al. Expression and cellular localization of classic NADPH oxidase subunits in the spontaneously hypertensive rat kidney. Hypertension. 2002;39:269–274
   PubMed Web of Science ®Google Scholar
• Babior BM. NADPH oxidase. Curr Opin Immunol. 2004;16:42–47
   PubMed Web of Science ®Google Scholar
• Yousefipour Z, Hercule H, Oyekan AO, Newaz MA. Antioxidant U74389G improves glycerol-induced acute renal failure without affecting PPARgamma gene. Ren Fail. 2007;29(7):903–910
   PubMed Web of Science ®Google Scholar
• Baliga R, Ueda N, Walker P, Shah S. Oxidant mechanisms in toxic acute renal failure. Drug Metab Rev. 1999;31:971–997
   PubMed Web of Science ®Google Scholar
• Shah SV, Walker PD. Reactive oxygen metabolites in toxic acute renal failure. Ren Fail. 1992;14(3):363–370
   PubMed Web of Science ®Google Scholar
• Zager RA. Rhabdomyolysis and myohemoglobinuric acute renal failure. Kidney Int. 1996;49:314–326
   PubMed Web of Science ®Google Scholar
• Marx N, Bourcier T, Sukhova GK, Libby P, Plutzky J. PPAR-activation in human endothelial cells increases plasminogen activator inhibitor type-1 expression: PPARg as a potential ediator in vascular disease. Arterioscler Thromb Vasc Biol. 1999;19:546–551
   PubMed Web of Science ®Google Scholar
• Vinik A, Parson H, Ullal J. The role of PPARs in the microvascular dysfunction in diabetes. Vascul Pharmacol. 2006;45(1):54–64
   PubMedGoogle Scholar
• Panunti B, Fonseca V. Effects of PPAR gamma agonists on cardiovascular function in obese, non-diabetic patients. Vascul Pharmacol. 2006;45(1):29–35
   PubMedGoogle Scholar
• Blaschke F, Spanheimer R, Khan M, Law RE. Vascular effects of TZDs: new implications. Vascul Pharmacol. 2006;45(1):3–18
   PubMedGoogle Scholar
• Yousefipour Z, Hercule H, Truong L, Oyekan A, Newaz M. Ciglitazone, a peroxisome proliferator-activated receptor gamma inducer, ameliorates renal preglomerular production and activity of angiotensin II and thromboxane A2 in glycerol-induced acute renal failure. J Pharmacol Exp Ther. 2007;322(2):461–468
   PubMedGoogle Scholar
• Hwang J, Kleinhenz DJ, Rupnow HL, et al. The PPARgamma ligand, rosiglitazone, reduces vascular oxidative stress and NADPH oxidase expression in diabetic mice. Vascul Pharmacol. 2007;46(6):456–462
   PubMedGoogle Scholar
• Inoue I, Noji S, Awata T, et al. Bezafibrate has an antioxidant effect: peroxisome proliferator-activated receptor a is associated with Cu2+/Zn2+-superoxide dismutase in the liver. Life Sci. 1998;63:135–144
   PubMed Web of Science ®Google Scholar
• Bagi Z, Koller A, Kaley G. PPARg activation, by reducing oxidative stress, increases NO bioavailability in coronary arterioles of mice with Type 2 diabetes. Am J Physiol Heart Circ Physiol. 2004;286:H742–H748
   PubMed Web of Science ®Google Scholar
• Mishra OP, Pooniya V, Ali Z, Upadhyay RS, Prasad R. Antioxidant status of children with acute renal failure. Pediatr Nephrol. 2008;23(11):2047–2051
   PubMedGoogle Scholar
• Yamanobe T, Okada F, Iuchi Y, Onuma K, Tomita Y, Fujii J. Deterioration of ischemia/reperfusion-induced acute renal failure in SOD1-deficient mice. Free Radic Res. 2007;41(2):200–207
   PubMed Web of Science ®Google Scholar
• Newaz M, Blanton A, Fidelis P, Oyekan A. NAD(P)H oxidase/nitric oxide interactions in peroxisome proliferator activated receptor (PPAR)alpha-mediated cardiovascular effects. Mutat Res. 2005;579(1–2):163–171
   PubMedGoogle Scholar
• Perianayagam MC, Orfeas L, Kolyada AY, et al. NADPH oxidase p22phox and catalase gene variants are associated with biomarkers of oxidative stress and adverse outcomes in acute renal failure. J Am Soc Nephrol. 2007;18:255–263
   PubMed Web of Science ®Google Scholar
• Nishiyama A, Kusaka T, Kitajima H. Role of aldosterone in oxidative stress and renal injury. Yakugaku Zasshi. 2007;127(9):1331–1337
   PubMed Web of Science ®Google Scholar
• Nangaku M, Fujita T. Activation of the renin-angiotensin system and chronic hypoxia of the kidney. Hypertens Res. 2008;31(2):175–184
   PubMedGoogle Scholar
• Coughlan MT, Cooper ME, Forbes JM. Renal microvascular injury in diabetes: RAGE and redox signaling. Antioxid Redox Signal. 2007;9(3):331–342
   PubMedGoogle Scholar
• Modlinger PS, Wilcox CS, Aslam S. Nitric oxide, oxidative stress, and progression of chronic renal failure. Semin Nephrol. 2004;24(4):354–365
   PubMedGoogle Scholar
• Newaz M, Yousefipour Z, Oyekan A. Role of PPAR-gamma on the pathogenesis and vascular changes in glycerol-induced acute renal failure. Pharmacol Res. 2006;54(3):234–240
   PubMedGoogle Scholar
• Yoshida T, Kurella M, Beato F, et al. Monitoring changes in gene expression in renal ischemia-reperfusion in the rat. Kidney Int. 2002;61(5):1646–1654
   PubMed Web of Science ®Google Scholar